SCHEMBL21906817

SCHEMBL21906817

O=C1CCC(N2C(=O)c3ccc(N4CCN(CCC5CNC5)CC4)cc3C2=O)C(=O)N1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 19/20 0.69
▸ DDB1 Q16531 11/20 0.52
▸ ALDH1A1 P00352 1/20 0.50
▸ CHRM2 P08172 1/20 0.50
▸ OPRM1 P35372 1/20 0.50
▸ IKZF3 Q9UKT9 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ HPGDS O60760 1/20 0.49
▸ CCNC P24863 1/20 0.48
▸ CDK8 P49336 1/20 0.48
▸ IRAK1 P51617 1/20 0.48
▸ NTRK3 Q16288 1/20 0.48
▸ HASPIN Q8TF76 1/20 0.48
▸ CDK19 Q9BWU1 1/20 0.48
▸ IRAK4 Q9NWZ3 1/20 0.48
▸ IRAK3 Q9Y616 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29648377 0.91 CRBN (0.67) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL22290046 0.91 CRBN (0.67) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL24501729 0.91 CRBN (0.67) CRBNDDB1ALDH1A1CHRM2OPRM1
Hydrochloric Acid SCHEMBL31373761 0.91 CRBN (0.66) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL29927679 0.90 CRBN (0.71) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL20231272 0.90 CRBN (0.71) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL22291391 0.88 CRBN (0.67) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL29259997 0.87 CRBN (0.72) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL30144407 0.87 CRBN (0.72) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL25035168 0.87 CRBN (0.64) CRBNDDB1ALDH1A1CHRM2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384063-B2 Modulators of estrogen receptor proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2022-07-12 — — US disclosed
US-20200199107-A1 MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas, Inc. 2020-06-25 — — US disclosed
US-10604506-B2 Modulators of estrogen receptor proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2020-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604506-B2 Modulators of estrogen receptor proteolysis and associated methods of use ADRM1, MDM2, ESR2 CRBN 5/4885DDB1 424/4885ALDH1A1 2935/4885
US-11384063-B2 Modulators of estrogen receptor proteolysis and associated methods of use ADRM1, MDM2, ESR2 CRBN 5/4885DDB1 424/4885ALDH1A1 2935/4885
US-20200199107-A1 MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE ADRM1, MDM2, ESR2 CRBN 5/4885DDB1 424/4885ALDH1A1 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback